Patents by Inventor Claes Ohlsson

Claes Ohlsson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11963057
    Abstract: After receiving a handover command (22) that commands a wireless device (16) to perform a make-before-break handover (24), the wireless device (16) continues to receive from a source link (20-0) downlink data packets for an unacknowledged mode bearer (21), until after the wireless device (16) establishes a connection with the target link (20-1) as part of the handover. After the wireless device (16) establishes the connection with the target link (20-1), the wireless device (16) receives from the target link (20-1) downlink data packets for the unacknowledged mode bearer (21). The wireless device (16) preserves a downlink data packet sequence number receiver status for the unacknowledged mode bearer (21), by using the same downlink data packet sequence number receiver status for the unacknowledged mode bearer (21) before and after the handover.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: April 16, 2024
    Assignee: Telefonaktiebolaget LM Ericsson (publ)
    Inventors: Oscar Ohlsson, Johan Rune, Claes-Göran Persson
  • Patent number: 10413555
    Abstract: The aim of the present study was to investigate the effect of a combination of triiodothyroacetic acid (TRIAC) and dehydroepiandrosterone (DHEA) compared with TRIAC, DHEA or placebo alone on corticosteroid induced effect on collagen synthesis in humans. Six healthy male human volunteers aged 40-65 participated. Four areas of abdominal skin were pre-treated for 3 weeks with betamethasone valerate cream. The same areas were then treated with one of the following alternatives in the same cream vehicle: TRIAC, DHEA, TRIAC+DHEA and placebo for 2 weeks. Then suction blisters were raised in each of these areas with a vacuum pump. The blister fluid from each area was collected and frozen until analysis. Analysis of amino terminal propeptide of human type I procollagen (PINP) in suction blister fluid was performed using a commercially available immunoassay (Orion Diagnostics) kit.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: September 17, 2019
    Assignee: TROPHEA DEVELOPMENT AB
    Inventors: Jan Faergemann, Gudmundur Johannsson, Claes Ohlsson, Derek Gregory Batcheller, Jörgen Johnsson, Jan Törnell
  • Publication number: 20190216822
    Abstract: The aim of the present study was to investigate the effect of a combination of triiodothyroacetic acid (TRIAC) and dehydroepiandrosterone (OHEA) compared with TRIAC, DHEA or placebo alone on corticosteroid induced effect on collagen synthesis in humans. Six healthy male human volunteers aged 40-65 participated. Four areas of abdominal skill were pre-treated for 3 weeks with betamethasone valerate cream. The same areas were then treated with one of the following alternatives in the same cream vehicle: TRIAC, DHKA, TWAC+DHEA and placebo for 2 weeks. Then suction blisters were raised in each of these areas with a vacuum pump. The blister fluid from each area was collected and frozen until analysis. Analysis of amino terminal propeptide of human type I procollagen (MNP) in suction blister fluid was performed using a commercially available immunoassay (Orion Diagnostics) kit.
    Type: Application
    Filed: March 22, 2019
    Publication date: July 18, 2019
    Applicant: TROPHEA DEVELOPMENT AB
    Inventors: Jan Faergemann, Gudmundur Johannsson, Claes Ohlsson, Derek Gregory Batcheller, Jörgen Johnsson, Jan Törnell
  • Patent number: 10285997
    Abstract: The aim of the present study was to investigate the effect of a combination of triiodothyroacetic acid (TRIAC) and dehydroepiandrosterone (DHEA) compared with TRIAC, DHEA or placebo alone on corticosteroid induced effect on collagen synthesis in humans. Six healthy male human volunteers aged 40-65 participated. Four areas of abdominal skin were pre-treated for 3 weeks with betamethasone valerate cream. The same areas were then treated with one of the following alternatives in the same cream vehicle: TRIAC, DHEA, TRIAC+DHEA and placebo for 2 weeks. Then suction blisters were raised in each of these areas with a vacuum pump. The blister fluid from each area was collected and frozen until analysis. Analysis of amino terminal propeptide of human type I procollagen (PINP) in suction blister fluid was performed using a commercially available immunoassay (Orion Diagnostics) kit.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: May 14, 2019
    Assignee: TROPHEA DEVELOPMENT AB
    Inventors: Jan Faergemann, Gudmundur Johannsson, Claes Ohlsson, Derek Gregory Batcheller, Jörgen Johnsson, Jan Törnell
  • Patent number: 10245290
    Abstract: The present invention relates to at least one probiotic strain chosen from Lactobacillus paracasei, or at least one probiotic strain chosen from Lactobacillus paracaseiin combination with at least one probiotic strain chosen from Lactobacillus plantarum, for use in the treatment or prevention of osteoporosis or for use in increasing the absorption of at Ca2+ ions, in a mammal, preferably in a human.
    Type: Grant
    Filed: April 3, 2014
    Date of Patent: April 2, 2019
    Assignee: Probi AB
    Inventors: Anna Berggren, Niklas Larsson, Gunilla Önning, Irini Lazou Ahrén, Klara Sjögren, Claes Ohlsson
  • Publication number: 20170319598
    Abstract: The aim of the present study was to investigate the effect of a combination of triiodothyroacetic acid (TRIAC) and dehydroepiandrosterone (DHEA) compared with TRIAC, DHEA or placebo alone on corticosteroid induced effect on collagen synthesis in humans. Six healthy male human volunteers aged 40-65 participated. Four areas of abdominal skin were pre-treated for 3 weeks with betamethasone valerate cream. The same areas were then treated with one of the following alternatives in the same cream vehicle: TRIAC, DHEA, TRIAC+DHEA and placebo for 2 weeks. Then suction blisters were raised in each of these areas with a vacuum pump. The blister fluid from each area was collected and frozen until analysis. Analysis of amino terminal propeptide of human type I procollagen (PINP) in suction blister fluid was performed using a commercially available immunoassay (Orion Diagnostics) kit.
    Type: Application
    Filed: November 24, 2015
    Publication date: November 9, 2017
    Applicant: TROPHEA DEVELOPMENT AB
    Inventors: Jan Faergemann, Gudmundur Johannsson, Claes Ohlsson, Derek Gregory Batcheller, Jörgen Johnsson, Jan Törnell
  • Publication number: 20160067289
    Abstract: The present invention relates to at least one probiotic strain chosen from Lactobacillus paracasei, or at least one probiotic strain chosen from Lactobacillus paracaseiin combination with at least one probiotic strain chosen from Lactobacillus plantarum, for use in the treatment or prevention of osteoporosis or for use in increasing the absorption of at Ca2+ ions, in a mammal, preferably in a human.
    Type: Application
    Filed: April 3, 2014
    Publication date: March 10, 2016
    Inventors: Anna Berggren, Niklas Larsson, Gunilla Önning, Irini Ahrén Lazou, Klara Sjögren, Claes Ohlsson
  • Publication number: 20060211671
    Abstract: This invention relates to the field of estrogen receptors and particularly though not exclusively on the effect of estrogen receptors and ligands for estrogen receptors on the prevention or treatment of obesity. The invention also relates to the effect of estrogen receptors and their ligands on lipoprotein levels in mammals.
    Type: Application
    Filed: September 30, 2005
    Publication date: September 21, 2006
    Inventors: Claes Ohlsson, Jan-Ake Gustafsson, Margaret Warner, Bo Angelin
  • Publication number: 20040214769
    Abstract: This invention relates to the field of estrogen receptors and particularly though not exclusively on the effect of estrogen receptors and ligands for estrogen receptors on the prevention or treatment of obesity. The invention also relates to the effect of estrogen receptors and their ligands on lipoprotein levels in mammals.
    Type: Application
    Filed: January 6, 2004
    Publication date: October 28, 2004
    Inventors: Claes Ohlsson, Jan-Ake Gustafsson, Margaret Warner, Bo Angelin
  • Publication number: 20020151732
    Abstract: This invention relates to the field of estrogen receptors and particularly though not exclusively on the effect of estrogen receptors and ligands for estrogen receptors on the prevention or treatment of obesity. The invention also relates to the effect of estrogen receptors and their ligands on lipoprotein levels in mammals.
    Type: Application
    Filed: November 26, 2001
    Publication date: October 17, 2002
    Inventors: Claes Ohlsson, Jan-Ake Gustafsson, Margaret Warner, Bo Angelin